Omeros | OMER - Selling And Administration Expenses

Stock Price
11.51
Daily Change
-0.08 -0.69%
Monthly
2.49%
Yearly
53.98%
Q1 Forecast
11.68

Omeros reported $11.32M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Adma Biologics USD 23.05M 320K Sep/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Cytokinetics USD 91.72M 67.02M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Heron Therapeutics USD 23.34M 4.18M Sep/2024
Immunic USD -0.24 0.03 Sep/2024
Insmed USD 212.48M 26.11M Dec/2025
Knight Therapeutics CAD 25.48M 119K Sep/2024
MacroGenics USD 9.9M 600K Sep/2025
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 91.87M 70K Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Rockwell Medical USD 4.04M 330K Jun/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
United Therapeutics USD 190.6M 38.6M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025
Xoma USD 11M 2.54M Jun/2024